Small Cap Feast
Small Cap Feast – 03 June 2019
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 896
Total number of AIM Companies trading: 820*
* As at 24 May 2019
Set Menu NEX Growth:
Total number of NEX Growth Market Companies (Incl Susp): 89*
Total number of NEX Growth Market Companies trading: 87*
* As at 24 May 2019
Set Menu Standard List:
Total number of Standard List Companies (Incl Susp): 161*
Total number of Standard List Companies trading: 140*
* As at 24 May 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
V22 Plc has left the NEX Exchange today.
V22 Plc has left the NEX Exchange today.
What’s Cooking in the IPO Kitchen?
Main Market (Premium)
Trainline—Seeking £75m raise. Proceeds to target a net debt at IPO of c.2x LTM Adjusted EBITDA) . In FY 2019, Trainline achieved net ticket sales of £3.2bn, and revenue of £210m. Due June
Main Market (Standard)
*Sareum (SAR.L) 0.68p £17.11m
Sareum announced that positive preliminary efficacy data from Phase 1/2 clinical trials with SRA737 in advanced cancer were presented at ASCO 2019 – potential path to registration outlined
30% response rate for SRA737 + low dose gemcitabine (LDG) in anogenital cancer
Anti-cancer activity demonstrated across multiple indications and genetic profiles
Sierra Oncology to discuss clinical findings and next steps for SRA737 at Analyst & Investor Event and live webcast today at 12:00 BST
“We are extremely encouraged by the preliminary clinical data that Sierra announced from its clinical programme with SRA737 at ASCO over the weekend. The results demonstrate the exciting potential of SRA737 in patients whose cancer type and genetic profile may confer and enhance sensitivity to this novel drug candidate, and open pathways for its advancement into the next stages of development towards registration. We look forward to providing updates on this exciting prospect as further progress is made and important development milestones are reached.” Sierra Oncology webcast today at noon.
Panther Metals (NEX:PALM) 0.7p £4.1m
Panther has put in an application for licence EL32140, named Annaburroo Gold Project by the Company, in the Northern Territory, Australia. The licence covers an area of 150km2 and is located approximately 105km southeast of Darwin.
Darren Hazelwood, Chief Executive Officer, commented:
“I’m delighted we have been able to extend our reach into Australia, and particularly the Northern Territory, so quickly following the announcement of our maiden application on 20 May 2019.
ELA covers an area of c. 150km2 and contains several highly prospective structural targets and gold geochemical anomalies, many of which require follow-up.
Newmont Australia identified the Donkey Hill prospect on the southern end of the Annaburroo Dome, which yielded 61.2 g/t Au and 50.8 g/t Au from grab samples and 5m @ 6.68 g/t Au in trenching.
Limited previous drilling at Donkey Hill provided near surface intercepts including 2m @ 3.10 g/t Au.
Tatton Asset Management (TAM.L) 214p £111.26m
The investment management and IFA support services group, today announces its preliminary results for the year ended 31 March 2019.
Discretionary assets under management (“AUM”) increased 24.5% to £6.1bn (2018: £4.9bn)
AUM net inflows increased to £1.1bn averaging over £90m per month
Group revenue increased 12.9% to £17.5m (2018: £15.5m)
Adjusted operating profit1 up 12.3% to £7.3m (2018: £6.5m)
Adjusted operating profit1 margin 41.7% (2018: 42.1%)
Reported profit before tax increased to £6.1m (2018: £3.6m), after charging exceptional items of £0.5m and share option costs of £0.9m
Proposed final dividend of 5.6p, giving a full year dividend of 8.4p
Adjusted fully diluted EPS2 increased 9.9% to 10.0p (2018: 9.1p)
Strong financial position, with net cash of £12.2m (2018: £10.6m)
Sirius Real Estate (SRE.L) 64.20p £1,327.19m
“The leading operator of branded business parks providing conventional space and flexible workspace in Germany, has completed the acquisition of a business park in Teningen, north of Freiburg, for €6.5 million, including acquisition costs, reflecting an EPRA net initial yield of 8.3%. The vendor is the Ascom Group, a Swiss healthcare solution provider. Notarised on 22 March 2019, the acquisition has been funded from existing cash resources.
The business park is well located in the economically strong metropolitan region of Freiburg, which is located in the Federal State of Baden Württemberg in the South West of Germany and in the vicinity of Strasbourg (France) and Basel (Switzerland), with easy access to the A5 Hamburg – Basel motorway and the national rail network.
The property provides lettable area of 20,000 sqm (40% warehouse/production space; 38% offices; 19% laboratory; and, 3% of other space) on a 43,000 sqm site. It is currently leased to seven tenants, with occupancy at 88% and producing annual net operating income of €542,000. The weighted average lease expiry is 1.6 years.”
4d Pharma (DDDD.L) 97.5p £63.86m
The “pharmaceutical company leading the development of Live Biotherapeutics, today announces the presentation of a poster detailing its Phase I/II clinical study of MRx0518 combined with KEYTRUDA® in patients with solid tumours who have failed prior anti-PD-1 therapy at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA. ASCO is the world’s largest conference in the field of clinical oncology and attracts approximately 39,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
The poster describes the proposed mechanism of action of MRx0518 and preclinical data in addition to details about the Phase I/II study which is currently enrolling patients .”
TP Group (TPG.L) 7.03p £53.76m
The “specialist services and engineering group, has entered into a nine year exclusive licensing agreement with Batelle Inc, to be a technology partner for their innovative nanotechnology material, SAMMS (the “Agreement”). The Agreement enables TP Group to develop and deploy carbon dioxide (CO2) removal equipment for transportation and life support systems in ground, marine, air and space vehicles.
Batelle Inc. is a global research and development organisation, headquartered in Columbus, Ohio in the United States. Their facility at Pacific Northwest National Laboratory has produced a new nanostructured sorbent material. SAMMS was originally developed under funding from the US Department of Energy to bind mercury from contaminated groundwater. It has many other applications including the treatment of carbon dioxide.”
Argo Blockchain (ARB.L) 6.35p £15.42m
The UK-based provider of enterprise-scale cryptomining services, has experienced significantly better than expected trading conditions and results following its circular released on 18 April and the operational update released on 8 May 2019.
The Company’s results for May were materially ahead of internal budgets, prompting the directors to review and significantly raise their expectations for the second quarter of this year.
The Company now anticipates generating the equivalent of 420 BTC of crypto assets on Argo’s balance sheet by the end of Q2, which at $8,575 USD per BTC (being the BTC price as at 31 May 2019), amounts to approximately £2.85 million. This is approximately £1 million or 57% higher than the previously announced estimate of £1.81m,
Beowulf Mining (BEM.L) 6.62p £38.26m
The “Nordic focused mineral exploration and development company, is pleased to announce that recent drilling at Aitolampi has extended the higher-grade Western Zone.
Oy Fennoscandian Resources AB (“Fennoscandian”), the Company’s graphite business, is pursuing a strategy to develop a ‘resource footprint’ of natural flake graphite prospects that can provide ‘security of supply’ and help to enable Finland to achieve its ambition of self-sufficiency in battery manufacturing. Fennoscandian is also seeking to move downstream and develop its know-how in processing and manufacturing of value-added graphite products.”
Drill hole AITDD19019 intersected 102.04m at 5.07 per cent TGC, which included 46.68m at 6.09 per cent TGC.
Angus Energy (ANGS.L) 3.15p £19.26m
Brockham Operations Update : after consideration of the recent results of the Brockham work programme, preparatory operations for the second stage will commence on the week of 17th June 2019.
The further preparatory work aims to ensure the borehole is in optimum condition for testing, and to give the best possible communication between the well and the fracture system in the formation. Once this has been completed then, subject to agreement of partners, well testing can commence to ascertain whether commercial hydrocarbon flows can be achieved from the BRX4Z well as envisaged per our timetable of 3 April.
Europa Oil & Gas (EOG.L) 2.75p £12.90m
“The UK and Ireland focused oil and gas exploration, development and production company, is pleased to announce that it has completed the sale of its 20% interest in the UK onshore PEDL143 exploration licence to AIM listed UK Oil & Gas PLC (‘UKOG’) for a consideration of £300,000, satisfied through the issue of 25,951,557 shares (‘Consideration Shares’) in UKOG, and as outlined in the announcement dated 16 April 2019. The Consideration Shares issued to Europa are subject to a six-month orderly market provision. “
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.